About this visual
Four pre-EASD updates on CagriSema, VK2735, enicepatide, and petrelintide. These are topline findings from separate clinical programs, so their results should not be compared directly.
Sources & further reading
Company announcements: Novo Nordisk: CagriSema REIMAGINE 5 and REDEFINE 9 topline results ↗
Company announcements: Viking Therapeutics: VK2735 maintenance-study topline results ↗
Company announcements: Roche: Phase II enicepatide results in adults with type 2 diabetes ↗
Company announcements: Zealand Pharma: initiation of the Phase 3 ZUPREME petrelintide program ↗
These are company topline announcements from separate programs. Trial populations, doses, durations, and comparators differ; the results are not head-to-head comparisons.




A lot of obesity medicine pipeline news dropped this week, and EASD hasn’t even started yet.
Here’s the quick rundown on four exciting updates that stood out to me.
🔹 CagriSema
Novo Nordisk released new Phase 3 data using the lower CagriSema dose of 1.0 mg cagrilintide + 1.0 mg semaglutide.
In REIMAGINE 5, adults with type 2 diabetes lost 12.4% with CagriSema 1.0/1.0 mg versus 9.1% with tirzepatide 5 mg at 60 weeks.
Important context: this was specifically against tirzepatide 5 mg, not 10 or 15 mg.
In REDEFINE 9, that same CagriSema 1.0/1.0 mg dose produced 21.0% mean weight loss at 68 weeks in adults with overweight or obesity.
To me, the interesting part is how much efficacy Novo is seeing at a dose well below the 2.4/2.4 mg CagriSema dose studied in some of the earlier trials.
🔹 VK2735
Viking Therapeutics, Inc. reported 16.3% to 18.7% mean weight loss at 21 weeks across weekly dose groups.
A small exploratory cohort that stayed on 17.5 mg weekly reached 21.7% at 33 weeks.
The part I found most interesting was maintenance. After weekly treatment, participants maintained up to 97% of their prior weight loss with every-other-week dosing and up to 90% with monthly dosing over the next 12 weeks.
That raises the possibility that some future obesity medications may eventually use less-frequent dosing for maintenance.
🔹 Enicepatide (CT-388)
Roche reported Phase 2 data in adults with type 2 diabetes and overweight or obesity.
At 48 weeks, the 24 mg dose produced:
• 15.5% mean weight loss
• 2.65 percentage-point mean HbA1c reduction
• 90% reached HbA1c ≤6.5%
• 62% reached HbA1c <5.7%
One number that has gotten a lot of attention is the 4.13-point HbA1c reduction seen in participants who started with an HbA1c above 8.5%. That is a subgroup result, not the overall trial average, but still pretty incredible.
🔹 Petrelintide
Zealand Pharma and Roche also announced the start of the Phase 3 ZUPREME program for petrelintide, a once-weekly amylin analog.
The program will include about 7,000 participants across three Phase 3 trials.
In prior Phase 2 data, petrelintide produced up to 10.7% mean weight loss at 42 weeks, with an encouraging GI tolerability profile at the maximally effective dose.
Overall, this week’s news is a good reminder that the next phase of obesity treatment is not just about who can produce the biggest weight-loss number.
Dose optimization, maintenance strategies, glycemic control and tolerability are all becoming important.
And EASD starts next week, so there is a lot more coming!
#ObesityMedicine #Obesity #GLP1 #CagriSema #VK2735 #Enicepatide #Petrelintide #WeightManagement #ClinicalTrials